Kornimate/medical-research-clean huggingface dataset:
a 3-day course for cfs/me

Conditions: Chronic Fatigue Syndrome; Myalgic Encephalomyelitis

Summary: chronic fatigue syndrome/myalgic encephalomyelitis (cfs/me) can be a serious and disabling condition with a heavy symptom burden and low function. work disability is common, and social life dramatically affected. cfs/me is a challenging health problem as well as a societal problem. in recent years, a doubling of the number of patients with a cfs/me diagnoses has been reported in norway. the patient group represents a challenge for the health care system, the municipality, and the norwegian labour and welfare organization (nav). according to new figures, the nav pays 100 million norwegian kroner (nok) each month in permanently incapacitated expenses for people with cfs/me. municipalities have expenses in form of care, rehabilitation and other measures. there is a lack of effective treatment for cfs/me. evidence-based knowledge is highly needed. if the 3-day course shows promising effects, this could have positive consequences for patients, relatives and health personnel, but also financially for the society and the municipality.

this is a randomized controlled trial (rct) to investigate potential effects (positive and negative) of a 3-day course with follow-up for 100 adults with cfs/me. the 3-day course used in this trial is named the lightning process (lp). the course is built on the lp manual (parker, 2013) and includes stress theory, positive psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology. positive and negative effects of the course on symptoms, disability and quality of life will be investigated, and a long-term follow-up of work participation conducted. any adverse events experienced during or after the 3-day course will be handled according to protocol.

Eligibility criteria:
inclusion criteria: * cfs/me diagnosis based on the canada consensus criteria. * at least 50% out of school/work. * readiness to change (corresponding to the preparation phase in transtheoretical model) * has given informed consent. exclusion criteria: * assessed by a general practitioner (gp): * underlying physical illness or mental disorder that may explain the symptoms. * suicide risk/previous suicide attempts. * pregnancy. * bedridden and in need of continuous care. * insufficient norwegian speaking or writing skills to participate in the 3-day course and fill out questionnaires.

Keywords: health education chronic fatigue syndrome/myalgic encephalopathy (cfs/me) rct 3-day course physical function fatigue cognitive techniques behavioral activation
celiac disease: nutrition education in primary school

Conditions: Celiac Disease

Summary: celiac disease is a chronic immune-based intestinal pathology. its prevalence is 1% and its incidence has increased in recent years. this disease usually causes gastrointestinal and/or extraintestinal symptoms, which can only be reduced by following a strict, lifelong gluten-free diet. in addition, the social life of people with celiac disease is impaired due to the impact of the gluten-free diet on daily activities. an adequate nutrition education program can improve the physical and social health of these people. moreover, considering the high impact this disease has on the people close to the celiac patient, and due to the important role that general population has in the care and inclusion of persons with celiac disease, education should be directed to general population. therefore, the purpose of zeliakide program is to promote nutrition education in general population. in particular, the specific aims are 1) to promote the social inclusion of people with celiac disease by raising awareness among the general population, and 2) to promote a balanced diet and an interest in science and research among children. zeliakide is an intervention aimed at children and focused on the school environment, and is based on inquiry based learning (ibl) methodology. inquiry-based teaching-learning sequence (tls) has been created to internalize and integrate competences related to celiac disease, gluten, gluten-free diet, balanced diet and healthy lifestyle. in addition, this tls aims to develop scientific competence through activities that promote science and the research process. although nutrition education programs for children have proven to be effective, it has been observed that children's interest in science has decreased. the investigators therefore aim to implement a nutrition education programme based on previous experiences that promotes science skills and stimulates children's interest in science.


Eligibility criteria:
inclusion criteria: * school must show interest in participating in the project. * children study in a primary school that must be used to project based learning. * have at least one class in grades 5th and 6th level of primary school. exclusion criteria: * family or closed relationship with school students.

Keywords: celiac disease nutrition education children gluten-free diet balanced diet
autologous adipose-derived stromal vascular fraction for treatment of post covid-19

Conditions: Covid19

Summary: this study is an early feasibility study to evaluate the safety of a single intravenous injection of autologous adipose-derived svf produced using the gid svf-2 device system for treatment of continuing respiratory distress after recovery from covid-19.

the gid svf-2 device is indicated for use for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of continuing respiratory distress after recovery from covid-19. the primary objective of this study is to evaluate the safety of a single intravenous injection of autologous adipose-derived svf for treatment of continuing respiratory distress after recovery from initial covid-19 infection. the secondary objective is preliminary assessment of feasibility of a single intravenous injection of autologous adipose-derived svf for treatment of continuing respiratory distress after recovery from covid-19.

Eligibility criteria:
inclusion criteria: 1. subjects that are ambulatory and previously hospitalized for a confirmed diagnosis of covid-19 using rt-pcr test 2. male or female subjects between the ages of 18-75 3. spo2 \> 92% on room air 4. subjects with bmi ≥22 5. subjects with forced vital capacity (fvc) ≥ 40% predicted and ≤ 70% predicted 6. subjects with dlco ≥ 20% predicted and ≤ 70% predicted 7. study subjects must be willing to voluntarily give written informed consent to participate in the study before any study procedures are performed 8. subjects with the ability to speak, read and understand english 9. subjects with the ability to complete follow up as specified in the protocol exclusion criteria: 1. subjects taking immunosuppressive drugs 2. subjects with history of lung malignancy 3. subjects allergic to lidocaine or epinephrine 4. women that are pregnant or planning to become pregnant during the study 5. women that are lactating 6. women on hormonal contraceptives in the past 30 days 7. women currently on hormone replacement therapy 8. subjects with chronic kidney disease stage 4 and stage 5 9. subjects with a history of pulmonary embolism 10. subjects with a history of anti-phospholipid syndrome 11. subjects participating in any other clinical study 12. subjects with history of deep vein thrombosis 13. subjects with history of cirrhosis with pugh classification of b or c 14. subjects on hemodialysis 15. subjects with organ dysfunction or predisposed to organ dysfunction (i.e., pre-dialysis \& orthopnea) 16. subjects with a history of prior clotting disorders or thrombotic syndrome 17. subjects with myocardial infarction within the past 2 months 18. subjects with blood pressure \ 160/100 mmhg or mean arterial pressure \ 120 mmhg 19. subjects with a history of drug or alcohol abuse 20. pulse \ 140 bpm 21. cardiac rhythm showing rapid atrial fibrillation with heart rate \>120 bpm or ventricular tachycardia
shmt1 polymorphism in parkinson's disease,

Conditions: Study the Role of SHMT1 Polymorphism in Parkinson Disease

Summary: parkinson disease (pd) is the most common movement disorder and represents the second most common degenerative disease of the central nervous system . shmt has been shown to be associated with various diseases.

this case -control observational prospective study will conducted on 40 patients with pd.

Eligibility criteria:
inclusion criteria: * patients age ≥ 50 years. * patients with pd diagnosed according to the united kingdom parkinson's disease society brain bank (uk pds brain bank diagnostic criteria) exclusion criteria: * patients with parkinsonian plus syndrome * patients with secondary parkinsonism * patients with other chronic comorbidities (renal, hepatic, and endocrinal disturbances and chronic chest disease.) * past and /or present history of epilepsy. * patients with disturbed conscious level.

Keywords: shmt1 polymorphism parkinson disease
role of axumin pet scan in germ cell tumor

Conditions: Testis Cancer; Germ Cell Tumor; Testicular Cancer; Germ Cell Tumor of Testis; Germ Cell Tumor, Testicular, Childhood; Testicular Neoplasms; Testicular Germ Cell Tumor; Testicular Yolk Sac Tumor; Testicular Choriocarcinoma; Testicular Diseases; Germ Cell Cancer Metastatic; Germ Cell Neoplasm of Retroperitoneum; Germ Cell Cancer, Nos

Summary: investigators will use axumin pet/ct to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

investigators aim to perform a prospective study of anti-18f-facbc pet/ct in patients with nsgct prior to rplnd, either in the primary setting or in the post-chemotherapy setting. we will correlate histopathologic outcomes from the rplnd specimen and clinical outcomes of recurrence during follow-up to identify the accuracy of anti-18f-facbc pet/ct in these settings.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed nsgct after orchiectomy who are scheduled to undergo primary rplnd or post-chemotherapy rplnd * patients must be over 18 years old and capable and willing to provide informed consent. * medically stable as judged by patient's physician. * life expectancy must be estimated at \> 6 months. * patients must have an ecog performance status of 0-3 (restricted to ecog ps 0-2 if age \>70 years). * patient must be able to lie still for a 20 to 30 minute pet/ct scan. patients will be asked if they have problems or issues with lying flat exclusion criteria: * patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to anti-18f-facbc are not eligible. * patients with liver failure are not eligible. * patients currently undergoing chemotherapy or chemotherapy within two weeks of anti-18f-facbc pet/ct scan are not eligible

Keywords: retroperitoneal lymph node dissection testicular cancer testis cancer germ cell tumor pet scan axumin teratoma
intraoperative systemic arterial hypotension secondary to beach positioning

Conditions: Hypotension

Summary: this study aims at describing the systemic arterial hypotension secondary to intraoperative beach chair positioning. this is a non-interventional prospective study. the primary endpoint will be the intraoperative systemic arterial pressure measured at the arm. the secondary endpoints will include postoperative mortality, intensive care admission, post anesthesia care unit length of stay,


Eligibility criteria:
inclusion criteria: * age above 18 years * patient operated in a sitting position at hopitaux universitaires de strasbourg * patient willing to participate in the study exclusion criteria: * refusal to participate in the study

Keywords: hypotension systemic blood pressure
empagliflozin versus sitagliptin therapy for improvement of myocardial perfusion reserve in diabetic patients with coronary artery disease

Conditions: Diabetes Mellitus; Coronary Disease

Summary: this trial evaluates the effects of empagliflozin versus sitagliptin, in addition to standard of care, on global myocardial perfusion reserve using dynamic single-photon emission computed tomography (spect) images.


Eligibility criteria:
inclusion criteria: * men or women at least 19 years of age * type 2 diabetes mellitus * stable coronary artery disease * global myocardial perfusion reserve (mpr) index \< 2.5 * the patient or guardian agrees to the study protocol and the schedule of clinical and dynamic spect follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site. exclusion criteria: * contraindications to empagliflozin, sitagliptin * dpp4 inhibitors or sodium-glucose cotransporter-2(sglt2) inhibitors within the previous 4 weeks * insulin requiring diabetes * poor glucose control (hba1c\>10 %) * acute coronary syndrome * stent placement within the previous 6 months * previous coronary artery bypass graft surgery within the previous 6 months * planned revascularization within 6 months * heart failure requiring loop diuretics * severe left ventricular hypertrophy (left ventricular septal wall thickness \> 13mm) * significant renal disease manifested by creatinine clearance of \< 30 ml/min) * hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (alanine transaminase or aspartate aminotransferase \> 3 times upper limit of normal) * radiopaque material implanted in the chest wall (metal, silicone, etc.) * contraindication to adenosine stress test * any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study. * patient's pregnant or breast-feeding or child-bearing potential * expected life expectancy \< 1 year * unwillingness or inability to comply with the procedures described in this protocol

Keywords: empagliflozin sitagliptin myocardial perfusion reserve
quality of life in patients with malignant biliary obstruction

Conditions: Gallbladder Cancer; Liver Cancer; Bile Duct Cancer

Summary: you may have symptoms like itching, abdominal pain, loss of appetite, fatigue, fevers and chills. the treatment you will receive to relieve the blockage is also intended to relieve symptoms and improve your quality of life. the purpose of this study is to find out if relieving the blockage in your bile duct improves your quality of life.

malignant biliary obstruction (mbo) may arise in patients with cholangiocarcinoma, pancreatic carcinoma, primary gallbladder carcinoma, hepatocellular carcinoma, or metastatic disease to the liver or portal lymph nodes. mbo is often accompanied by significant symptoms that may result in impairment of health-related quality of life (hrql), including pruritus, fever, nutritional deficits, abdominal pain, nausea and vomiting, and fatigue. approaches to the relief of mbo include surgical bypass and/or resection, percutaneous drainage with or without biliary stenting, or endoscopic stenting. the non surgical procedures may be done prior to attempted curative resection or for palliation in individuals with unresectable or recurrent disease.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of malignant biliary obstruction * radiologic or histologic evidence of mbo * percutaneous biliary drainage procedure planned or * surgical biliary enteric bypass, or hepatic resection with biliary reconstruction (high bile duct tumors) planned * kps \>50% * age 18 years or greater * able to speak and read english * able to comprehend and execute informed consent * prior intervention for mbo not exclusionary exclusion criteria: * unable to complete questionnaire due to performance status * proxy completion is not accepted * medical or psychiatric condition that, in the judgment of the investigator, prevents appropriate comprehension and execution of either the informed consent or the study instrument

Keywords: quality of life
investigating magnesium glycinate in structure/function role of hot flashes.

Conditions: Hot Flashes

Summary: the goal of this study is to further evaluate the effect of magnesium on the symptoms of menopause, specifically vasomotor symptoms (vms) in breast cancer patients and/or women at an elevated risk of breast cancer.

hot flashes are one of the most common symptoms that are experienced in women during perimenopause, menopause, and as a result of treatment of cancer such as breast cancer. hot flashes, also known as vasomotor symptoms (vms) may decrease a woman's quality of life due to discomfort, disruption of daily life, interruption of sleep, and worsening of depression. previously, estrogen-based therapy was the primary treatment choice for vms. however, in recent years, this has been considered less favorable due to the increased risk of breast cancer associated with estrogen-based therapy. while medications such as certain antidepressants, gabapentin and clonidine are available as non-hormonal treatment options, they appear to be less effective in comparison to estrogen therapy with reported adverse effects. magnesium supplementation has been found to have very promising results in alleviating vms in patients with a history of breast cancer. the goal of this study is to further investigate the effects of administering magnesium supplementation in reducing the effects of hot flashes in this targeted population. our aim is to create a controlled trial using different dosages of magnesium glycinate in the management of hot flashes. participants will be asked to complete surveys for data collection and analysis.

Eligibility criteria:
inclusion criteria: * age: 25-85 years. * women with a history of invasive breast cancer, dcis, or lcis * creatine labs drawn within 90 days as part of standard of care. * bothersome hot flashes (defined by their occurrence of two or more hot flashes a day and/or of sufficient severity to prompt the patient to seek therapeutic intervention). * presence of hot flashes for \>30 days prior to study entry. * ability to complete questionnaire(s) by themselves or with assistance. * ability to provide informed written consent. * life expectancy ≥6 months. * willing to work with the enrolling institution for follow-up (during the active monitoring phase of the study). * ecog performance status (ps) = 0, 1. exclusion criteria: * pregnancy (assessed on intake questionnaire. positive answer exclusionary) * any of the following current (≤4 weeks prior) or planned therapies: * antineoplastic chemotherapy (anti-her2 agents allowed) * androgens * estrogens (any delivery route) * progestogens * tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period * ssris/snris * gabapentin * clonidine * oxybutinin * stage iv or v renal disease or gfr\<30 in the last 90 days
fluorouracil, cisplatin, and radiation therapy in treating patients with stage ii, stage iii, or stage iv nasopharyngeal cancer

Conditions: Head and Neck Cancer

Summary: rationale: drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. radiation therapy uses high-energy x-rays to damage tumor cells. combining fluorouracil and cisplatin with radiation therapy may kill more tumor cells. purpose: this phase ii trial is studying how well giving fluorouracil and cisplatin together with radiation therapy works in treating patients with stage ii, stage iii, or stage iv nasopharyngeal cancer.

objectives: primary * determine progression-free survival of patients with previously untreated stage iib-ivb nasopharyngeal cancer treated with fluorouracil, cisplatin, and radiotherapy. secondary * determine overall survival and response rate in patients treated with this regimen. * determine compliance to this regimen in these patients. * determine the toxicity of this regimen in these patients. outline: this is a multicenter study. patients receive chemotherapy comprising fluorouracil iv continuously on days 1-5 and cisplatin iv continuously on days 6-7. beginning 2-3 days after the completion of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 4 weeks. with 2-3 days between each course, patients receive a second course of chemotherapy, undergo a second course of radiotherapy, and then receive a third course of chemotherapy. treatment continues in the absence of unacceptable toxicity or disease progression. patients are followed for 3 years. projected accrual: a total of 90 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically confirmed nasopharyngeal cancer (npc) * type i-iii disease by who classification * stage iib-ivb disease by tnm classification with no distant metastases by chest x-ray, liver ultrasonography or ct scan, and bone scintigraphy * lymph node metastases evaluated by ct scan, mri, and palpation * progression range of primary lesion evaluated by mri and pharyngeal fiberoptic endoscopy patient characteristics: age * 18 to 70 performance status * ecog 0-2 life expectancy * not specified hematopoietic * wbc \> 3,500/mm\^3 * platelet count \> 100,000/mm\^3 hepatic * no severe hepatic dysfunction renal * creatinine clearance \> 60 ml/min * no severe renal dysfunction cardiovascular * no severe cardiac dysfunction pulmonary * no severe pulmonary dysfunction other * no other active cancer prior concurrent therapy: biologic therapy * no prior biologic therapy for npc chemotherapy * no prior systemic chemotherapy for npc endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: stage ii lymphoepithelioma of the nasopharynx stage iii lymphoepithelioma of the nasopharynx stage iv lymphoepithelioma of the nasopharynx stage ii squamous cell carcinoma of the nasopharynx stage iii squamous cell carcinoma of the nasopharynx stage iv squamous cell carcinoma of the nasopharynx
safety evaluation of exablate mrgfus for prostate cancer

Conditions: Prostate Cancer

Summary: evaluate the safety, compatibility and imaging quality of the exablate mrgfus system.

the objective of this study is to evaluate safety, compatibility and imaging quality of the exablate mrgfus system for prostate cancer, under simulated use conditions. no acoustic energy will be delivered and no focused ultrasound therapy will be performed. this is an imaging only study.

Eligibility criteria:
inclusion criteria: * age of patients: up to 75 years. * men scheduled for radical prostatectomy due to prostate cancer. * patients who are able and willing to give consent and able to attend all study visits. exclusion criteria: * contraindications to mri including: claustrophobia, weight over 120 kg, implanted ferromagnetic materials or foreign objects, and known intolerance to the mri contrast agent (e.g. gadolinium or magnevist) * severely abnormal coagulation (inr\>1.5) * patients with unstable cardiac status including: unstable angina pectoris on medication, patients with documented myocardial infarction within six months of protocol entry, congestive heart failure requiring medication (other than diuretic), patients on anti-arrhythmic drugs, severe hypertension (diastolic bp \> 100 on medication), and patients with cardiac pacemakers * severe cerebrovascular disease (multiple cva or cva within 6 months) * individuals who are not able or willing to tolerate the required prolonged stationary supine position during imaging (approximately 1 hrs.) * any rectal pathology preventing probe insertion, (as active proctitis, ulcerative colitis, fissure ani, diverticulitis, previous rectal surgery, ibd, etc...) * any spinal pathology that prohibits maintaining supine position for more then an hour * any previous radiation to the pelvis.

Keywords: exablate mrgfus focused ultrasound magnetic resonance imaging prostate cancer radical prostatectomy candidate